Allergan BIOCELL Breast Implant Recall Lawsuit

Note: This content is provided for informational purposes only. Douglas & London is no longer accepting cases related to Allergan BIOCELL Breast Implant-related injuries.

Allergan Breast Implant Recall History

On July 24, 2019, Allergan announced a recall of certain BIOCELL textured breast implants after reports showed a possible link between the implants and a type of non-Hodgkin’s lymphoma.

In December 2018, sales of textured Allergan breast implants
were suspended in all 33 countries in Europe as well as Israel, Brazil, and
Australia. Canada suspended Allergan’s license for its BIOCELL breast implants
in May 2019 after an internal safety review concluded that these implants were
linked to an increased risk of cancer. Before the recall, there was enough
evidence to halt sales of Allergan’s BIOCELL breast implants in many countries
across the world.

Allergan BIOCELL Breast Implants Linked to Cancer

Reports have shown that people with Allergan’s BIOCELL
textured products were six times more likely to develop breast
implant-associated anaplastic large cell lymphoma (BIA-ALCL) than people with
textured implants from other manufacturers.

The World Health Organization officially designated BIA-ALCL as a form of T-cell lymphoma that can develop following breast implantation.

NOTE: Douglas & London is a law firm and cannot provide medical advice. If you have medically related questions or concerns regarding any side effects that you may be experiencing or a recall notice you may have received, please contact your surgeon for more information.